NNNN - Company ID 0001982708
Anbio Biotechnology trades as NNNN and has a market capitalization of $1.50 B, making it the #2355 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $8.65M, up 5.6% from the prior year and net income of $6.40M. This page tracks Anbio Biotechnology through 40 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-05-29
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from 42.5% to 74.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-19 |
| 6-K | - | 2026-04-27 |
| 20-F/A | - | 2026-04-09 |
| New insider ownership | 3 | 2026-04-08 |
| New insider ownership | 3 | 2026-04-08 |
| New insider ownership | 3 | 2026-04-08 |
| New insider ownership | 3 | 2026-04-08 |
| New insider ownership | 3 | 2026-04-08 |
The largest companies sharing Anbio Biotechnology's SEC industry classification (in vitro & in vivo diagnostic substances).
Anbio Biotechnology (NNNN) has a market capitalization of $1.50 B as of 2026-05-29, ranking #2355 among US-listed companies.
Anbio Biotechnology reported revenue of $8.65M for fiscal year 2025, an increase of 5.6% year over year.
Yes. Anbio Biotechnology reported net income of $6.40M in its latest fiscal year.